Catalyst Pharmaceuticals to Showcase Real-World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference [Yahoo! Finance]
Catalyst Pharmaceuticals to Showcase Real-World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
Why Catalyst Pharmaceuticals (CPRX) Is Up 5.4% After Raising 2026 Revenue Guidance And Highlighting Rare Disease Portfolio [Yahoo! Finance]
Catalyst Pharmaceuticals (CPRX) was upgraded by Zacks Research from "hold" to "strong-buy".
Catalyst Pharmaceuticals (CPRX) had its price target raised by Citigroup Inc. from $33.00 to $35.00. They now have a "buy" rating on the stock.